



Slide 2







Slide 5





Slide 7 **Focus for today** relioping the CPGs; Diagnosis of Upper Quadrant Lymphedema Secondary to Cancer; Clinical Practice Guideline from the Academy of Oncologic Physical Therapy of the APTA Interventions for Breast Cancer-Related Lymphedema: A Clinical Practice Guideline from the Academy of Oncologic Physical Therapy of the APTA Infographic for clinicians APTA Kentuc Slide 8 Oncology section of the American Physical Therapy Association (APTA) recognized the importance of using the evidence to support clinical practice Supporting Practice with Evidence EDGE Work Group on BC-related lymphedema Published recommendations in 2014 Needed to expand this work and provide further guidance/recommendations · Volunteers - claire.davies@bhsi.com Slide 9 **Introduction to CPGs and CPSs Clinical Practice Guideline** "...statements that include recommendations intended to optimize patient care that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options" —AHRQ

Clinical Practice Statements

 Statement on clinical practice based on a review and critique of existing and sometimes conflicting guidelines – American College of Physicians

Identify an important clinical question What is current best practice for the diagnosis, assessment, and management of Upper Quadrant Lymphedema secondary to Cancer? In July 2012 the Oncology Section sent a small group to a CPG development workshop to start the process. Identified the question and wrote a small grant to APTA

Slide 11




Slide 12

Process With assistance of Academic Reference Librarians (SLU and USC) developed search strategy and executed search Difficulty not excluding relevant articles so had an expansive search lymphedema, Elephantiasis, and truncated text words lymphedema", elephantiasis Excluded: filariasis, parasites, congenital, hereditary, as well as editorial, letter, and comment

Slide 13 **Review of Literature** Literature Searches began in January 2000 Pubmed, CINAHL, Cochrane, AHBO, National Guideline Clearinghouse, Scopus, SPORTDiscus with Full Full, PEDNo Physiotherapy Evidence Database, OTseeker Occupational Therapy Systematic Evaluation of Evidence Diagnostic CPG search through July 2015 Total Articles – 9,247 Included - 91 Intervention CPG search through March 2019 Total Articles – 13,033 Included – 163 APTA Kentuc A Chapter of Exclusion Criteria: Non-cancer, Lower Extremity, Animal Models, Surgical/Pharmacological Approaches, Case Studies Slide 14 **Quality Rating Tools** All articles were rated for risk of bias using established quality rating tools Assessment: Reliability: QAREL (Lucas 2010, 2013) Validity: QUADAS (Whiting 2003, 2011) Diagnostic Accuracy: QUADAS (Whiting 2003, 2011) Interventions: Critical Appraisal Tool –Experimental Intervention (APTA, 2018) 018) - Developed by APTA, 2018 – to review quality of intervention trials - <u>High quality</u>: Appropriate patient population; Randomized, Controlled Trial; Tester Binded; Sufficient follow-up', Valid and Reliable Outcome Meas Adequate Sample Size; Appropriate Statistical Analysis Slide 15 **Preliminary** Recommendation Statements Constructed Based on the quality of evidence (APTA CPG Manual) Grade & High quality studies (Level I) with moderate to substantial benefit/harm — "Must/Should" or "Must not/Should not" Grade & High Level studies (Level I) with slight to moderate benefit/harm OR Moderate level evidence (Level II) for moderate level benefit/harm "Should" or "Should not" Grade C. Moderate level evidence (Level II) for slight level benefit or harm OR Weak level evidence (level III) Grade C. Best Pactice of the Grade Reviews (Level III) Grade P. Best Pactice — based on current clinical norms or expert opinion



Slide 17



Slide 18


Summary of Diagnosis of Upper Quadrant Lymphedema Secondary to Cancer: #1

Clinical Practice Guideline From the Oncology Section of the American Physical Therapy Association

2017

Levenhagen K, Davies C, Perdomo M, Ryan SK, Gilchrist L. Diagnosis of Upper Quadrant Lymphedema Secondary to Cancer: Clinical Practice Guideline From the Oncology Section of the American Physical Therapy Association

Practice Guidelines C, Paris K, Perdomo M, Gilchrist L. Pathabilitation Oncology Section of the American Physical Therapy Association Physical Predom Oncology 2018;36(3): £11-£18.



Slide 20

BIA/BIS Recommendation

- BIA may be used for detecting early-stage lymphedema in patients with breast cancer that are at risk for developing BCRL
- patients with preast cancer that are at risk for developing BCRL

 Pre-operative assessment may provide better accuracy

 Reliability may decline in moderate to late-stage lymphedema due to tissue changes/fibrosis

 Cost of the equipment and electrodes needs to be factored into decision
- Prospective Surveillance Models
- Risk for false positive and false negative results
 Recommended that it be integrated with other asset
- NOTE: studies used the U400 model not SOZO



Slide 21

- Strong evidence to support reliability and validity
- Moderate evidence to support diagnostic accuracy
 Inter-limb Volume difference of ≥200 mL helps to rule in LE
 Falling below 200 mL cut-point may not rule out LE (Smoot, 2011)

- Falling below 200 mL cut-point may not rule out LE (bmoet, 2013)

 Recommendation:
 Calculate volume for diagnosis of arm lymphedema
 If falls below 200 mL cut-point and potential for early or treated LE, use a different method to assist with diagnosis
 Not interchangeable with WD, perometry or BIS
 Will reflect parallel changes
 Pre-op baseline measure for comparison may provide better accuracy with diagnosis using 5% change as criteria
 For HN cancer, use upper neck measure
 For hand LE, use Figure of 8 method

Circumferential Measurement: Recommendation



Slide 22 **Water Displacement** Due to its excellent reliability, water displacement has been considered the reference standard in much of the validity and diagnostic accuracy research (Brorson 2012, Taylor 2006, Lee 2010, Sander 2002, Karges 2003, Gjorup 2010, McKinnon 2007) Validity and diagnostic accuracy revealed variability of quality ratings necessitating the need for more rigorous evidence Recommendations: At this time, strong evidence exists to support the reliability, strong/moderate evidence for validity and moderate evidence for diagnostic accuracy and thus it is recommended for detection of upper extremity lymphedema. Clinically, time constraints, set up, and cross-contamination limits its utility Slide 23 **Perometry Recommendation** • Strong evidence to support the reliability Moderate quality evidence to support validity No evidence to support diagnostic accuracy Recommendation: At this time, perometry has been used primarily in research is not currently recommended due to lack of diagnostic accuracy studies. The expense, bulkiness, and availability in the US also limits its clinical usefulness. Slide 24 **Ultrasound Recommendation** • Only weak to moderate level evidence is available for reliability Validity yielded mixed results in moderate quality studies • 1 high quality study on the diagnostic accuracy; sensitivity was only acceptable at a few sites in the arm and specificity was acceptable Recommendation: At the time of the CPG, US may be used to identify tissue changes in SUQL but requires cautious interpretation as well as other measures for diagnostic purposes

APTA

Slide 25 **Emerging Diagnostic** Tissue Dielectric Constant Recommendation: While TDC is a promising new measure for SUQL that may be incorporated into clinical practice, other diagnostic measures should also be used Lymphoscintigraphy Recommendation: At the time of the CPG, lymphoscintigraphy was not recommended for diagnosing SUQL but is emerging as an important tool prior to surgical intervention Slide 26 Clinical Practice Guideline: #2 Non-surgical, Non-pharmacological **Intervention Guidelines** 2020 Davies et al. Interventions for Breast Cancer-Related Lymphedema: Clinical Practice Guidelines from the Academy of Oncologic Physical Therapy of the APTA. Physical Therapy. 2020;100(7):1163-1179. Slide 27 Construction of Intervention

CPG - SR

Literature Confirm inclusion/exclusion
 Study design
 Appropriate outcome measure
 Data can be extracted Review APTA's CAT-EI review tool

Slide 29

Critical Appraisal Tool-Experimental Interventions **Review Tool** (CAT-EI Tool)

- Developed by APTA to review quality of intervention trials : Includes ratings of: Population Blinding Control groups : Outroo groups : Outroo groups : Outroome measure reliability and validity : Sample size : Rated for each outcome measured

- High quality: Appropriate patient population; Randomized, Controlled Trior; Tester Blinded; Sufficient follow-up; Valid and Reliable Outcome Measure; Adequate Sample Size; Appropriate Statistical Analysis
- Acceptable Quality: Appropriate patient population; Randomized; Lesser follow-up; Valid and Reliable Outcome Measure; Adequate Sample Size; Appropriate Statistical Analysis




Slide 30

Criteria

- Inclusion criteria
 English publications • 2000 to 2019
- Upper quadrant cancer related lymphedema Lymphedema intervention primary study objective
- Exacerbation or onset of lymphedema
- Quality of evidence score of high or acceptable


- Exclusion criteria
 Non-English publications
- Not within the eligible time period
- Not within the eligible time per
 Lower extremity or non-cancer related lymphedema
 Lymphedema intervention not primary or secondary study objective
- Abstract only Duplicates





Slide 32







Slide 35



Slide 36

Prospective Surveillance Model For High-risk groups - may identify subclinical lymphedema early to improve outcome (C) Surveillance: Pre-operative assessment, Every three months for the first-year post-op Biannually for up to 5 years. Use volume measures or BIS for monitoring (C) If early subclinical lymphedema persists or progresses after initial conservative intervention refer for more intensive intervention – (CDT) (C)

Slide 37	aptaky.org	
	Education (BP)	
	All Patients and Survivors with a Cancer Diagnosis	
	Across the trajectory	
	 Pre-operative to lymphedema diagnosis Establish a patient centered plan of care 	
	 Modified based on clinical presentation and psychosocial factors Education will change based on risk and or established lymphedema 	
	present.	
	APTA Kentucky	
	COLTRACTOR STATE OF THE STATE O	
Slide 38	aptaky.org	
	The second is Francisco	
	Therapeutic Exercise	
	Safe and essential to individuals throughout the cancer trajectory Evidence refutes exercise as a risk factor for development or	
	exacerbation of lymphedema • Collaboration with clinician and healthcare team	
	• Consider	
	Other comorbidities Body system impairments	
	APTA Kentucky	
	Agentucky Agent for human Project Charge Agentician Agent Charge Agentican	
Slide 39	aptaky.org	
	What do we mean by cafe?	
	What do we mean by safe?	
	• <u>Did not result</u> in lymphedema in patient at risk for SUQL	
	Diagnosis of SUQL > 3 months post surgery	
	 <u>Did not cause</u> short or long-term exacerbation in patients with SUQL 	
	Determined during the study's follow up time period	
	• 24 hours to 2 years APTA Kentucky Schut Color	
	ACT RUCKY N	

Therapeutic Exercises: is a pre-exercise medical evaluation needed?

- No other comorbidities except cancer;
 Follow exercise recommendations with no pre-exercise medical evaluation
- Peripheral neuropathy, arthritis/musculoskeletal impairments, poor bone health, lymphedema
 Recommend pre-exercise medical evaluation and modify recommendations based on impairments

Cardiopulmonary disease, ataxia, extreme fatigue, severe nutritional deficiencies, hymphedema exacerbation, bone metastasis:

Need pre-exercise medical evaluation and collaboration with physician prior to exercise, modify exercise based on impairments



Slide 41

Therapeutic Exercises

Exercise Guidelines for Survivors of Cancer


All patients and survivors with a breast cancer diagnosis across the trajectory

• Aerobic exercise moderate intensity

- At least 3 times/week for 30 minutes And/or
- Resistance training
 2 times/week for 20-30 minutes

Campbell KL, Winters-Stone KM, Wildemann J, et al. Seeclas Gr 2019 Ct 11 127C, 2001. so 11 1240A4CC0000000000000115





Slide 43	aptaky.org	
	Complete Decongestive Therapy (CDT)	
	Phase I clinical:	
	Friase Tullinual. Manual Lymph Drainage (MLD), multi-layer short stretch compression bandage, exercise, skin hygiene, and education based on the individual's clinical	
	presentation and needs.	
	Phase II home care: A home care program initiated once volume reduction of the upper extremity has	
	stabilized. Skin care, exercises, self-MLD, and use of compression therapy.	
	Modified CDT (mCDT) = if CDT components were varied or omitted from the above description. APTA Kentucky	
	Kentucky Anima of the formation Proposed Theory Association The Control of the	
Slide 44	aptaky.org	
	Sub-clinical and Early-Stage Lymphedema (ISL	
	Stage 0 and I) Modified CDT (C)	
	Exercise (A) Compression Garment: Subclinical (C) Early Stage 1(A)	
	Self-MLD: Subclinical (C) Early Stage 1 (A) Skin and Nail Hygiene (BP)	
	Education: Subclinical (C) Early Stage 1 (A)	
	Monitor for Change or Increase in symptoms	
	If clinical presentation worsens with mCDT then progress to Phase I CDT. APTA Kentucky	
	A Coppin of the America Project Transport Association	
Slide 45	aptaky.org	
Slide 45	Moderate and Late Lymphedema	
	(ISL stage II and III)	
	CDT (B) Clinical Phase I	
	Exercise	
	Therapist applied MLD Compression bandaging	
	Education Skin hygiene	
	Compression garment	
	APTA Kenny M, Isan, S, S of Madillate reconstruct for exagurer channel reprinted recovering to the security. According to the security of th	

Moderate and Late Lymphedema (ISL stage II and III) CDT (8) Home Care Phase II Exercise Education Skin hygiene Self-MLD Compression garment O Night compression if appropriate Intermittent Compression Pump Long-term follow-up

Slide 47


Moderate and Late Lymphedema
(ISL Stage II and III)

Kinesio tape (B)
Use with CDT
No substitute for short-stretch compression bandage
Monitor for adverse events

Low-level laser therapy (B)
Use with CDT or compression

Slide 48

Slide 49 Reference for the flow diagrams for implementing the intervention CPG. • Ryans, K., Perdomo, M., Davies, C.C. *et al.* Rehabilitation interventions for the management of breast cancer–related lymphedema: developing a patient-centered, evidence-based plan of care throughout survivorship. *J Cancer Survi* (2021). https://doi.org/10.1007/s11764-021-00991-2 Slide 50 Remember Clinical Expertise Clinical experience is crucial in the process • Observe the individual in front of you • Find out their goals Research Evidence Patient • Be guided by the CPG Values Slide 51 CPG Limitations All of our higher/acceptable quality studies were performed on those with BCRL. Studies may have been published outside of review timeframe On-going effort to include additional articles published since March 2019 Non-published studies APTA



Slide 53





Now we are going to hold your hand, work together and help you learn a technique infographics - to implement an aspect of a **CPG** for Clinicians



Slide 56

References

- American Physical Therapy Association. APTA Clinical Practice Guideline Process Manual. 2018. VA: Alexandria.
- Davies C, Ryan K, Levenhagen K, Perdomo M. Breast Cancer EDGE Task Force Outcomes: Quality of Life and Functional Outcome Measures for Secondary Lymphedema in Breast Cancer Survivors. Rehabilitation Oncology, 2014; 32(1):7-12.
- Davies C, Levenhagen K, Ryans K, Perdomo M, Gilchrist L. Interventions for Breast Cancer-Related Lymphedema: A Clinical Practice Guideline from the Academy of Oncologic Physical Therapy of the APTA. Phys Ther. 2002;100(7):1163-1179.
- Davies et al. An Executive Summary of the APTA Academy for Oncologic Physical Therapy Clinical Practice Guideline: Interventions for Breast Cancer–Related Lymphedema. Rehabilitation Oncology. 2020; 38:103-109.
- Oriology, 2021, 36.103-103.

 Fisher M, Lee, Davies C, Geyer H, Colon G, Pfalzer L. Oncology Section EDGE Task Force on Breast Cancer Outcomes: A Systematic Review of Outcome Measures for Functional Mobility. Rehabilitation Oncology, 2015, 33(3): 19-31.
- Renabilitation Unicology, 2013; 34(3): 19-41.
 Fisher M, Davies C, Beuthin C, Colon G, 2oil B, Ffalzer L. Breast Cancer EDGE Task Force Outoc Clinical Measures of Strength and Muscular Indurance: A Systematic Review. Rehabilitation funciology, 2014; 3-14(6): 613.
 Fisher M, Lewangie P, Oncology Section Task Force on Breast Cancer Outcomes: Scapular Assessment. Rehabilitation Cincology, 2013; 30(4): 12-18.



Slide 57

References

- Harringen Maile S, Ebagh D. Break Caron: Edit Fals Force Outcomes: Clinical Measures of Health Related Quality of the Reepillo Processory. 2013. 3 pp. 5 pp. 6 pp. 6

- Levenhagen K, Davies P, Perdomo M, Ryans K, Gilchrist L. Diagnosis of Upper Quadrant Lymphedema Secondary to Cancer: Clinical Practice Guideline from the Oncology Section of the American Physical Therapy Association. Phys Therapy 2017; 37(1)-12. Co. politiline for in Residentiation Conclogy 2017; 33(1):E11.8.
 Lucis NP, Macaskill P, Invigi J, Sogdik N. The development of a quality appraisal tool for studies of diagnostic reliability (QMRL). Clinic platients 2015;63:S34–S81.
- Lucas N, Macaskill P, Irwig L, et al. The reliability of a quality appraisal tool for studies of diagnostic reliability (QAREL). BMC Med Res Methodol. 2013;13:111.
- Miale S, Harrington S, Kendig T. Oncology Section Task Force on Breast Cancer Outcomes: Clinical Measures
 of Upper Extremity Function. Rehabilitation Oncology. 2013; 30(4):27-34.



References

- Peridomo N. Pyrors X. Eventhogen K. Davies C. Gilchrist L. Clinical Implementation of the Clinical Procision Guideline for Disgroving Upper-Guadrant Lymphedema Secondary to Cancer Rehabilitation Oncology 738-33(3): 151-151.

 Peridomo M. Sebelski C. Davies C. Oncology 738-7 Force on Breast Cancer Outcomes: Shoulder and Glenohamard Outcome Messures. Rehabilitation oncology 2013; 30(4).

 Ryans et al. Rehabilitation interventions for the Management of Breast Cancer-Related Lymphedema: Develoging a Patient Centered, Evidence-Based Plant Of Care Throughout Survivorship. Journal of Cancer survivorship. Accepted January 2021.

 Whiting P. Rugies AVI, Rettama St. a. In The development of QUADAS: a tool for the quality and the Cancer Survivorship. Accepted January 2021.

 Res Methodol. 2003;3:25.

 Whiting P. Rugies AVI, Westwood M. et al. QUADAS 2: a revide tool for the quality assessment of diagnostic accuracy included in systematic reviews. *BMC Med*



n lan				